Embecta Corp.
| NASDAQ: EMBC | Healthcare / Drug Manufacturers / USA |
| 30.38 | +0.9500 | +3.23% | Vol 365.85K | 1Y Perf -33.74% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 28.80 | ASK | 34.00 | ||
| Open | 29.17 | Previous Close | 29.43 | ||
| Pre-Market | - | After-Market | 30.38 | ||
| - - | - -% |
| Target Price | 28.00 | Analyst Rating | Moderate Sell 3.77 | |
| Potential % | -7.83 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★ 50.22 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 44.06 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 31.44 | Earnings Rating | — | |
| Market Cap | 1.74B | Earnings Date | 14th Feb 2023 | |
| Alpha | -0.18 | Standard Deviation | 0.10 | |
| Beta | -1.73 |
Today's Price Range 29.0230.45 | 52W Range 22.3048.00 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.91% | ||
| 1 Month | -2.91% | ||
| 3 Months | 10.39% | ||
| 6 Months | 3.79% | ||
| 1 Year | -33.74% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -115.27 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | 25.50 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | 74.21 | |||
Return on invested Capital Q | 17.27 | |||
Return on invested Capital Y | 71.18 | |||
Assets Turnover | 1.00 | |||
Receivables Turnover | 6.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.40 | ||||
| 2.61 | ||||
| 1.67 | ||||
| 3.50 | ||||
| 3.80 | ||||
| 7.17 | ||||
| -1.56 | ||||
| -15.58 | ||||
| 2.75B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.50 | ||||
| 2.20 | ||||
| - | ||||
| - | ||||
| 6.60 | ||||
| Leverage Ratio | -1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 68.60 | ||||
| 36.50 | ||||
| 39.40 | ||||
| - | ||||
| 15.73 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 840.20M | ||||
| 14.69 | ||||
| -7.18 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.45 | ||||
| 0.60 | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2023 | 0.49 | 0.93 | 89.80 |
| Q04 2022 | 0.67 | 0.73 | 8.96 |
| Q03 2022 | 0.87 | 1.07 | 22.99 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | 0.51 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 365.85K |
| Shares Outstanding | 57.27K |
| Shares Float | 57.45M |
| Trades Count | 7.56K |
| Dollar Volume | 11.00M |
| Avg. Volume | 674.32K |
| Avg. Weekly Volume | 664.61K |
| Avg. Monthly Volume | 491.90K |
| Avg. Quarterly Volume | 866.45K |
Embecta Corp. (NASDAQ: EMBC) stock closed at 30.38 per share at the end of the most recent trading day (a 3.23% change compared to the prior day closing price) with a volume of 365.85K shares and market capitalization of 1.74B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2029 people. Embecta Corp. CEO is .
The one-year performance of Embecta Corp. stock is -33.74%, while year-to-date (YTD) performance is 20.13%. EMBC stock has a five-year performance of %. Its 52-week range is between 22.3 and 48, which gives EMBC stock a 52-week price range ratio of 31.44%
Embecta Corp. currently has a PE ratio of 6.40, a price-to-book (PB) ratio of 2.61, a price-to-sale (PS) ratio of 1.67, a price to cashflow ratio of 3.50, a PEG ratio of 2.32, a ROA of 25.50%, a ROC of 74.21% and a ROE of -115.27%. The company’s profit margin is 15.73%, its EBITDA margin is 39.40%, and its revenue ttm is $840.20 Million , which makes it $14.69 revenue per share.
Of the last four earnings reports from Embecta Corp., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.51 for the next earnings report. Embecta Corp.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Embecta Corp. is Moderate Sell (3.77), with a target price of $28, which is -7.83% compared to the current price. The earnings rating for Embecta Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Embecta Corp. has a dividend yield of 2.45% with a dividend per share of $0.60 and a payout ratio of -%.
Embecta Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 30.74, ATR14 : 1.27, CCI20 : -52.52, Chaikin Money Flow : -0.04, MACD : 0.03, Money Flow Index : 53.79, ROC : -1.46, RSI : 51.92, STOCH (14,3) : 56.57, STOCH RSI : 0.60, UO : 49.99, Williams %R : -43.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Embecta Corp. in the last 12-months were: David F. Melcher (Buy at a value of $100 781)
Embecta Corp.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
CEO:
Telephone: +1 201 847-6880
Address: 1 Becton Drive, Franklin Lakes 07417-1880, NJ, US
Number of employees: 2 029
